Pharmacy

Strategies to get the most value out of current and future oncology payment models

Phase 3 drugs show innovative approaches to cancer treatment.

Kootenai Care Network uses a population health management platform to reduce the burden on payers and providers.

Providing uniform and quality service to all patients, no matter their demographic.

Study finds use, costs for new migraine prevention meds projected to triple by 2020.

The opioid crisis cost the U.S. billions. Find out the impact on the future economy.

Despite the trust between physicians and patients, some physicians believe another prescription drug crisis may arise.

The state’s desired savings and efficiencies can be realized, but will likely take some effort.

Consumers will depend on the internet to research prescriptions and medical devices rather than a doctor’s referral.

First-of-its-kind survey brings clarity to the effect of 340B and Medicaid programs on each other through comprehensive state analysis.

An ingestible sensor allows physicians to remotely monitor TB patients’ medicine.

Why cost and treatment length are some of the biggest concerns for drug manufacturers.

Antimicrobial stewardship is a key strategy to combat the emergence of drug resistance.

Authorized generics have been gaining popularity with pharmaceutical manufacturers, but just how do they impact pharmacies?

One key opinion leader calls on healthcare to ensure access to gene therapies.

Expert shares the skills healthcare executives need for successful negotiation.

Payers grapple with expensive treatment payment options.

Cancer treatment is becoming more personalized. Here’s how.

The Medicare for All debate surrounds the 2020 election-but is it truly understood?

Findings suggest that racemic substitution for single-enantiomer drugs offers an opportunity for savings.

Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.

The policies and approaches healthcare leaders should promote.

What to expect for these high-dollar drugs.

The megamerger passes a federal judge’s scrutiny.

Does step therapy harm patient outcomes?